Cargando…
Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study
Background: We aimed to determine the anti-SARS-CoV-2 IgG antibodies among people living with HIV (PLHIV) in Pune, India. Methods: This cross-sectional study was conducted between March 2021 and June 2021. Demographic and clinical information related to coronavirus disease 2019 (COVID-19) were recor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832581/ https://www.ncbi.nlm.nih.gov/pubmed/35128977 http://dx.doi.org/10.1177/23259582221077943 |
_version_ | 1784648751379382272 |
---|---|
author | Ghate, Manisha Shidhaye, Pallavi Gurav, Shraddha Gadhe, Keshav Kale, Varsha Jain, Preeti Thakar, Madhuri |
author_facet | Ghate, Manisha Shidhaye, Pallavi Gurav, Shraddha Gadhe, Keshav Kale, Varsha Jain, Preeti Thakar, Madhuri |
author_sort | Ghate, Manisha |
collection | PubMed |
description | Background: We aimed to determine the anti-SARS-CoV-2 IgG antibodies among people living with HIV (PLHIV) in Pune, India. Methods: This cross-sectional study was conducted between March 2021 and June 2021. Demographic and clinical information related to coronavirus disease 2019 (COVID-19) were recorded on structured questionnaires. Blood samples were collected and tested for anti-SARS-CoV-2 IgG antibodies using commercial ELISA. Results: Of the 405 HIV infected individuals enrolled in the study, 223(55.1%) were females. Mean age and CD4 count of participants were 42 years (SD: 10) and 626 cells/mm(3) (SD: 284) respectively. A total of 382 (95%) PLHIV were virologically suppressed. The seropositivity against SARS-CoV-2 was found in 221 PLHIV (54.6%, 95% CI: 49.7-59.4). No significant association was found between demographic or clinical factors and seropositivity. Conclusion: A high prevalence of anti-SARS-CoV-2 IgG antibodies was found among PLHIV attending ART centre indicating an exposure to the virus among them. |
format | Online Article Text |
id | pubmed-8832581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-88325812022-02-12 Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study Ghate, Manisha Shidhaye, Pallavi Gurav, Shraddha Gadhe, Keshav Kale, Varsha Jain, Preeti Thakar, Madhuri J Int Assoc Provid AIDS Care COVID-19 and the Continuum of HIV Care and Prevention- Original Research Article Background: We aimed to determine the anti-SARS-CoV-2 IgG antibodies among people living with HIV (PLHIV) in Pune, India. Methods: This cross-sectional study was conducted between March 2021 and June 2021. Demographic and clinical information related to coronavirus disease 2019 (COVID-19) were recorded on structured questionnaires. Blood samples were collected and tested for anti-SARS-CoV-2 IgG antibodies using commercial ELISA. Results: Of the 405 HIV infected individuals enrolled in the study, 223(55.1%) were females. Mean age and CD4 count of participants were 42 years (SD: 10) and 626 cells/mm(3) (SD: 284) respectively. A total of 382 (95%) PLHIV were virologically suppressed. The seropositivity against SARS-CoV-2 was found in 221 PLHIV (54.6%, 95% CI: 49.7-59.4). No significant association was found between demographic or clinical factors and seropositivity. Conclusion: A high prevalence of anti-SARS-CoV-2 IgG antibodies was found among PLHIV attending ART centre indicating an exposure to the virus among them. SAGE Publications 2022-02-07 /pmc/articles/PMC8832581/ /pubmed/35128977 http://dx.doi.org/10.1177/23259582221077943 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | COVID-19 and the Continuum of HIV Care and Prevention- Original Research Article Ghate, Manisha Shidhaye, Pallavi Gurav, Shraddha Gadhe, Keshav Kale, Varsha Jain, Preeti Thakar, Madhuri Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study |
title | Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study |
title_full | Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study |
title_fullStr | Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study |
title_full_unstemmed | Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study |
title_short | Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study |
title_sort | seroprevalence of anti-sars-cov-2 igg antibodies among hiv infected individuals attending art centre at pune: a cross-sectional study |
topic | COVID-19 and the Continuum of HIV Care and Prevention- Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832581/ https://www.ncbi.nlm.nih.gov/pubmed/35128977 http://dx.doi.org/10.1177/23259582221077943 |
work_keys_str_mv | AT ghatemanisha seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy AT shidhayepallavi seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy AT guravshraddha seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy AT gadhekeshav seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy AT kalevarsha seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy AT jainpreeti seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy AT thakarmadhuri seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy |